- News
- Kisqali
Tag:
Kisqali
-
Swiss pharmaceutical giant Novartis AG expects currency-adjusted annual sales growth of 5% to 6% until 2030, driven largely by stronger-than-anticipated revenue from its leading cancer therapies, Kisqali and Scemblix.20 Nov 2025-10:39
-